Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg

Sulfadoxine-Pyrimethamine + Amodiaquine Tablets
  • Dosage: Sulfadoxine/Pyrimethamine 175 mg and Amodiaquine 75mg 
  • Packaging: 9 tablets/blister*10/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameSulfadoxine/Pyrimethamine + Amodiaquine Tablets (Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg Oral Tablets)
SpecificationEach tablet contains: Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientsSulfadoxine / Pyrimethamine / Amodiaquine
Pharmacological ClassAntimalarial Combination (Sulfonamide / Antifolate / 4-Aminoquinoline)
Route of AdministrationOral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Take at approximately the same time each day during the treatment course.
PackagingBlister pack (PVC-Alu) or strip pack, typically per treatment course
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life36 months (unopened)

Product Overview

This product is an oral antimalarial combination tablet containing Sulfadoxine/Pyrimethamine 175mg and Amodiaquine 75mg per tablet. It combines two classes of antimalarial agents: (a) a long-acting sulfonamide antifolate combination (sulfadoxine/pyrimethamine), and (b) a 4-aminoquinoline derivative (amodiaquine). The combination of two agents with complementary mechanisms of action is designed to provide effective antimalarial activity while also reducing the risk of parasite resistance development. The product is formulated as film-coated tablets for convenient oral administration.

Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg: What the Published Guidance Says

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.

Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Malaria & ACTs range overview.

  • The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
  • One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
  • ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)

We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.

Supply & Specification Data for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg

Product NameSulfadoxine/Pyrimethamine + Amodiaquine Tablets (Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg Oral Tablets)
SpecificationEach tablet contains: Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientsSulfadoxine / Pyrimethamine / Amodiaquine
Pharmacological ClassAntimalarial Combination (Sulfonamide / Antifolate / 4-Aminoquinoline)
Route of AdministrationOral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Take at approximately the same time each day during the treatment course.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupMalaria & ACTs — Malaria & ACTs
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.

Testing, Monographs & Batch Documentation

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Every batch of Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

The batch record for this product normally includes:

  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities
  • Testing for packaging integrity and seal testing
  • Testing for description and identification

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

Pack Configuration, Artwork & Shipping Documents

  • Pack size: Blister pack (PVC-Alu) or strip pack, typically per treatment course. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
  • Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.

Dossier, Authority Filings & Tender Documentation

Documents for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.

  • Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
  • CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
  • Site Master File and GMP certificate for the manufacturing workshops.

The context for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is its place among ACT regimens named in the WHO Model List of Essential Medicines. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.

Buyer Questions about Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg

What pack size is available for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg?

This presentation is normally supplied as Blister pack (PVC-Alu) or strip pack, typically per treatment course. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.

What documentation comes with a shipment of Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months.

Does the batch documentation for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg support a registration filing?

Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Which ACT combinations appear on the WHO Model List?

The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.

Do you supply dispersible paediatric ACTs?

Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.

Other Malaria & ACTs Products in This Range

Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.

Request a Quotation for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg

For tenders and programme supply, send the line item, pack size, quantity and destination for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg 175mg. We return a quotation with lead time, documentation list and sample availability in one response.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products